Cargando…

New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a Subgroup Analysis of the AMBORA Trial

Oral antitumor therapeutics (OAT) bear a high risk for medication errors, e.g., due to drug–drug or drug–food interactions or incorrect drug intake. Advanced age, organ insufficiencies, and polymedication are putting uro-oncological patients at an even larger risk. This analysis sets out to (1) inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Schlichtig, Katja, Cuba, Lisa, Dürr, Pauline, Bellut, Laura, Meidenbauer, Norbert, Kunath, Frank, Goebell, Peter J., Mackensen, Andreas, Dörje, Frank, Fromm, Martin F., Wullich, Bernd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369799/
https://www.ncbi.nlm.nih.gov/pubmed/35956173
http://dx.doi.org/10.3390/jcm11154558
_version_ 1784766583697047552
author Schlichtig, Katja
Cuba, Lisa
Dürr, Pauline
Bellut, Laura
Meidenbauer, Norbert
Kunath, Frank
Goebell, Peter J.
Mackensen, Andreas
Dörje, Frank
Fromm, Martin F.
Wullich, Bernd
author_facet Schlichtig, Katja
Cuba, Lisa
Dürr, Pauline
Bellut, Laura
Meidenbauer, Norbert
Kunath, Frank
Goebell, Peter J.
Mackensen, Andreas
Dörje, Frank
Fromm, Martin F.
Wullich, Bernd
author_sort Schlichtig, Katja
collection PubMed
description Oral antitumor therapeutics (OAT) bear a high risk for medication errors, e.g., due to drug–drug or drug–food interactions or incorrect drug intake. Advanced age, organ insufficiencies, and polymedication are putting uro-oncological patients at an even larger risk. This analysis sets out to (1) investigate the frequency and relevance of medication errors in patients with prostate cancer or renal cell carcinoma treated with OAT and (2) compile recommendations for clinical practice. This post-hoc subgroup analysis used data collected in the randomized AMBORA trial (2017–2020; DRKS00013271). Clinical pharmacologists/pharmacists conducted advanced medication reviews over 12 weeks after initiation of a new oral regimen and assessed the complete medication process for drug–related problems. Medication errors related to either the OAT, prescribed or prescription-free concomitant medication, or food were classified regarding cause and severity. We identified 67 medication errors in 38 patients within the complete medication within 12 weeks. Thereof, 55% were detected at therapy initiation, 27% were caused by the patients, and 25% were drug–drug or drug–food interactions. Problem-prone issues are summarized in a ‘medication safety table’ to provide recommendations for clinical practice in uro-oncology. Tailored strategies including intensified care by clinical pharmacologists/pharmacists should be implemented in clinical practice to improve medication safety.
format Online
Article
Text
id pubmed-9369799
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93697992022-08-12 New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a Subgroup Analysis of the AMBORA Trial Schlichtig, Katja Cuba, Lisa Dürr, Pauline Bellut, Laura Meidenbauer, Norbert Kunath, Frank Goebell, Peter J. Mackensen, Andreas Dörje, Frank Fromm, Martin F. Wullich, Bernd J Clin Med Article Oral antitumor therapeutics (OAT) bear a high risk for medication errors, e.g., due to drug–drug or drug–food interactions or incorrect drug intake. Advanced age, organ insufficiencies, and polymedication are putting uro-oncological patients at an even larger risk. This analysis sets out to (1) investigate the frequency and relevance of medication errors in patients with prostate cancer or renal cell carcinoma treated with OAT and (2) compile recommendations for clinical practice. This post-hoc subgroup analysis used data collected in the randomized AMBORA trial (2017–2020; DRKS00013271). Clinical pharmacologists/pharmacists conducted advanced medication reviews over 12 weeks after initiation of a new oral regimen and assessed the complete medication process for drug–related problems. Medication errors related to either the OAT, prescribed or prescription-free concomitant medication, or food were classified regarding cause and severity. We identified 67 medication errors in 38 patients within the complete medication within 12 weeks. Thereof, 55% were detected at therapy initiation, 27% were caused by the patients, and 25% were drug–drug or drug–food interactions. Problem-prone issues are summarized in a ‘medication safety table’ to provide recommendations for clinical practice in uro-oncology. Tailored strategies including intensified care by clinical pharmacologists/pharmacists should be implemented in clinical practice to improve medication safety. MDPI 2022-08-04 /pmc/articles/PMC9369799/ /pubmed/35956173 http://dx.doi.org/10.3390/jcm11154558 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Schlichtig, Katja
Cuba, Lisa
Dürr, Pauline
Bellut, Laura
Meidenbauer, Norbert
Kunath, Frank
Goebell, Peter J.
Mackensen, Andreas
Dörje, Frank
Fromm, Martin F.
Wullich, Bernd
New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a Subgroup Analysis of the AMBORA Trial
title New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a Subgroup Analysis of the AMBORA Trial
title_full New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a Subgroup Analysis of the AMBORA Trial
title_fullStr New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a Subgroup Analysis of the AMBORA Trial
title_full_unstemmed New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a Subgroup Analysis of the AMBORA Trial
title_short New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a Subgroup Analysis of the AMBORA Trial
title_sort new oral antitumor drugs and medication safety in uro-oncology: implications for clinical practice based on a subgroup analysis of the ambora trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369799/
https://www.ncbi.nlm.nih.gov/pubmed/35956173
http://dx.doi.org/10.3390/jcm11154558
work_keys_str_mv AT schlichtigkatja neworalantitumordrugsandmedicationsafetyinurooncologyimplicationsforclinicalpracticebasedonasubgroupanalysisoftheamboratrial
AT cubalisa neworalantitumordrugsandmedicationsafetyinurooncologyimplicationsforclinicalpracticebasedonasubgroupanalysisoftheamboratrial
AT durrpauline neworalantitumordrugsandmedicationsafetyinurooncologyimplicationsforclinicalpracticebasedonasubgroupanalysisoftheamboratrial
AT bellutlaura neworalantitumordrugsandmedicationsafetyinurooncologyimplicationsforclinicalpracticebasedonasubgroupanalysisoftheamboratrial
AT meidenbauernorbert neworalantitumordrugsandmedicationsafetyinurooncologyimplicationsforclinicalpracticebasedonasubgroupanalysisoftheamboratrial
AT kunathfrank neworalantitumordrugsandmedicationsafetyinurooncologyimplicationsforclinicalpracticebasedonasubgroupanalysisoftheamboratrial
AT goebellpeterj neworalantitumordrugsandmedicationsafetyinurooncologyimplicationsforclinicalpracticebasedonasubgroupanalysisoftheamboratrial
AT mackensenandreas neworalantitumordrugsandmedicationsafetyinurooncologyimplicationsforclinicalpracticebasedonasubgroupanalysisoftheamboratrial
AT dorjefrank neworalantitumordrugsandmedicationsafetyinurooncologyimplicationsforclinicalpracticebasedonasubgroupanalysisoftheamboratrial
AT frommmartinf neworalantitumordrugsandmedicationsafetyinurooncologyimplicationsforclinicalpracticebasedonasubgroupanalysisoftheamboratrial
AT wullichbernd neworalantitumordrugsandmedicationsafetyinurooncologyimplicationsforclinicalpracticebasedonasubgroupanalysisoftheamboratrial